Coloretti I, Genovese A, Teixeira J, Cherian A, Ferrer R, Landoni G
J Anesth Analg Crit Care. 2024; 4(1):13.
PMID: 38383521
PMC: 10882873.
DOI: 10.1186/s44158-024-00150-w.
Guzzo I, Paglialonga F
Pediatr Nephrol. 2023; 38(9):2907-2910.
PMID: 37087478
DOI: 10.1007/s00467-023-05985-z.
Jozwiak M
J Intensive Med. 2023; 2(4):223-232.
PMID: 36788938
PMC: 9924015.
DOI: 10.1016/j.jointm.2022.05.001.
Jozwiak M, Geri G, Laghlam D, Boussion K, Dolladille C, Nguyen L
Front Med (Lausanne). 2022; 9:826446.
PMID: 35677822
PMC: 9168038.
DOI: 10.3389/fmed.2022.826446.
Laghlam D, Jozwiak M, Nguyen L
Cells. 2021; 10(7).
PMID: 34359936
PMC: 8303450.
DOI: 10.3390/cells10071767.
Angiotensin II: a new therapeutic option for vasodilatory shock.
Bussard R, Busse L
Ther Clin Risk Manag. 2018; 14:1287-1298.
PMID: 30100727
PMC: 6067786.
DOI: 10.2147/TCRM.S150434.
Angiotensin in Critical Care.
Hall A, Busse L, Ostermann M
Crit Care. 2018; 22(1):69.
PMID: 29558991
PMC: 5861652.
DOI: 10.1186/s13054-018-1995-z.
Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II.
Tumlin J, Murugan R, Deane A, Ostermann M, Busse L, Ham K
Crit Care Med. 2018; 46(6):949-957.
PMID: 29509568
PMC: 5959265.
DOI: 10.1097/CCM.0000000000003092.
The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature.
Busse L, McCurdy M, Ali O, Hall A, Chen H, Ostermann M
Crit Care. 2017; 21(1):324.
PMID: 29282149
PMC: 5745607.
DOI: 10.1186/s13054-017-1896-6.
Angiotensin II in vasodilatory shock: lights and shadows.
Antonucci E, Agosta S, Sakr Y
Crit Care. 2017; 21(1):277.
PMID: 29137677
PMC: 5686834.
DOI: 10.1186/s13054-017-1869-9.
Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety.
Busse L, Wang X, Chalikonda D, Finkel K, Khanna A, Szerlip H
Crit Care Med. 2017; 45(8):1285-1294.
PMID: 28489648
PMC: 5515638.
DOI: 10.1097/CCM.0000000000002441.
Angiotensin II in septic shock.
Correa T, Takala J, Jakob S
Crit Care. 2015; 19:98.
PMID: 25886853
PMC: 4360936.
DOI: 10.1186/s13054-015-0802-3.
Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study.
Chawla L, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z
Crit Care. 2014; 18(5):534.
PMID: 25286986
PMC: 4212099.
DOI: 10.1186/s13054-014-0534-9.
Tumor necrosis factor-α: regulation of renal function and blood pressure.
Ramseyer V, Garvin J
Am J Physiol Renal Physiol. 2013; 304(10):F1231-42.
PMID: 23515717
PMC: 3651627.
DOI: 10.1152/ajprenal.00557.2012.
Angiotensin II in experimental hyperdynamic sepsis.
Wan L, Langenberg C, Bellomo R, May C
Crit Care. 2009; 13(6):R190.
PMID: 19948019
PMC: 2811902.
DOI: 10.1186/cc8185.
Angiotensin for septic shock unresponsive to noradrenaline.
Yunge M, Petros A
Arch Dis Child. 2000; 82(5):388-9.
PMID: 10799431
PMC: 1718307.
DOI: 10.1136/adc.82.5.388.
